

Occurrence of and radioanalytical methods used to determine medical radionuclides in environmental and biological samples. A review

J. Martínez, T. Baciú, A. Peñalver, C. Aguilar, F. Borrull *

Departament de Química Analítica i Química Orgànica, Universitat Rovira i Virgili, Unitat de Radioquímica Ambiental i Sanitària (URAI), Consorci d'Aigües de Tarragona (CAT), Carretera Nacional 340, Km. 1094, 43895, L'Ampolla, Tarragona, Spain

ARTICLE INFO

Keywords:

Medical radionuclides
Air
Urine
Wastewater
Sewage sludge
Sediments

ABSTRACT

Medical radionuclides are widely used in nuclear medicine practices today. Their production, handling and administration have different impacts on the environment and society due to the radioactive waste generated. Over recent years authors have taken an interest in the monitoring and safe disposal of this radiopharmaceutical waste, mainly in environmental and biological samples, and consequently a variety of radioanalytical methods for these matrices have been developed. The present review aims to outline the state of the art and the latest trends reported in the literature from 2007 to the present, focusing on the occurrence and determination of medical radionuclides in environmental and biological samples. Special attention is given to critically discussing the strengths and weaknesses of the different steps involved in determining medical radionuclides in these types of matrices. The methodologies presented are accompanied by examples.

1. Introduction

Nuclear medicine (NM) is a branch of medicine that uses non-encapsulated or unsealed radiopharmaceuticals to diagnose and treat various diseases. These radioactive compounds comprise a specific organic molecule labelled with a radionuclide. The radioisotopes used need to be selected taking into account a number of ideal requirements such as a) easy availability, b) relatively short effective half-life, and, depending on their final application, i.e. therapy or diagnostics, c) the type of radiation emitted. Table 1 lists the most commonly used radionuclides for diagnosis and therapy, with ^{99m}Tc and ^{131}I being the most widely administered for these purposes (Chain and Illanes, 2015; Orsini et al., 2010; Qaim, 2017; Saha, 2004; Zimmermann, 2006).

The handling of these unsealed radionuclides – as far as storage of radiation sources, internal transportation, production, preparation of radiopharmaceuticals and administration to patients are concerned – results in the generation of radioactive waste. Waste containing short half-life radioisotopes can be classified in a number of ways, such as a) airborne waste, b) liquid radioactive waste and c) solid radioactive waste, depending on the radionuclide itself, its use and its chemical and physical forms. All these types of waste may potentially be present not only in NM department areas but also outside these medical facilities

due to hospital and out-patient discharges (ARPANSA, 2008; Krawczyk et al., 2013; Ravichandran, 2017). Waste management is of the utmost importance since medical staff and the general public could potentially be exposed to external or internal radiation. Thus, the determination of medical radionuclides in environmental and biological samples originating from NM practices is a matter of concern for various researchers due to their increased use. It is therefore necessary to work continuously to develop monitoring methods aimed at improving the evaluation of possible occupational intake and the assessment of possible worker exposure.

The aim of this review is to present recent advances in the methodologies used to determine medical radionuclides in environmental and biological samples, from 2007 to the present. It includes descriptions of the different approaches presented in the literature aimed at determining these kinds of radionuclides in several types of matrices and a detailed discussion of the main advantages and drawbacks of the strategies reported. A number of examples are then given to illustrate current trends in the strategies reported in the literature, focusing especially on collection, pretreatment and measurement. Finally, the radiological content of the samples analysed are presented in terms of activity concentrations.

The review is divided into two parts including associated up-to-date tables. The first focuses on those radionuclides present in envi-

* Corresponding author.

Email address: francesc.borrull@urv.cat (F. Borrull)

Table 1
Usual radionuclides used for diagnostics and therapy, indicating their type of emission and half-life (Biersack and Freeman, 2007).

Use	Type of emission	Radioisotope	T _{1/2}
Diagnostic	γ	⁶⁷ Ga	3.26 d
		^{99m} Tc	6.0 h
		¹¹¹ In	2.83 d
		¹²³ I	13.10 h
		²⁰¹ Tl	73.10 h
	β ⁺	¹¹ C	20.48 min
		¹³ N	9.97 min
		¹⁵ O	2.04 min
		¹⁸ F	109.74 min
		³² P	14.30 d
Therapy	β ⁻	⁸⁹ Sr	50.50 d
		¹³¹ I	8.00 d
		¹⁸⁶ Re	3.70 d
		²²³ Ra	11.44 d
	α		
	Auger electron	⁶⁷ Ga	3.20 d

ronmental samples: a) air samples from inside the NM department work environment, which are used to assess the radiation hazard to exposed medical staff, and b) samples from areas surrounding a medical centre, such as sewage, wastewater treatment plant (WWTP) samples, surface water or sediments and biota, which are frequently analysed to monitor unsealed liquid radioactive waste from hospitals and its impact on the environment. Such discharges are released into the sewage system a) directly as controlled disposal, or b) after decay in abatement systems, although there is no common disposal strategy for the European Union (European Commission, 2000; Janssens et al., 2013; Petrucci and Traino, 2015). Patients' home excretions also contribute to the discharges that should be taken into account (Andrés et al., 2011; Barquero et al., 2008a, 2008b). The second part deals with biological samples, which can come from a) medical staff, these being used to evaluate the related committed effective dose at which they can be exposed, and b) treated patients, these being useful for assessing the radiation safety of family and medical workers helping these patients. One of the most commonly analysed biological samples is urine, since this is the main excretory pathway from the human body (International Atomic Energy Agency (IAEA), 2018). However, there are other biological samples that are also of interest, such as the air exhaled by patients, saliva and skin swabs, which are also taken into consideration in the present review (Castellani et al., 2013).

2. Environmental samples: radioanalytical methods

As explained in the Introduction, the medical radionuclides used in NM departments are usually present in environmental samples because of their handling and administration, and consequently they can be found in the waste generated. It is for this reason that over the past twelve years there has been much interest in their determination. The following sections (2.1 and 2.2) contain a detailed discussion focusing on the strengths and limitations of the analytical methods proposed in the literature for this purpose. The most relevant papers published over this period as regards indoor air samples are summarized in Table 2, which shows the specific collection, pretreatment and measurement strategies commonly applied with these types of sample, along with the radiological content in terms of activity concentrations of the different radionuclides found. All this information is also presented in Tables 3 and 4, but, referring to outdoor liquid and solid samples respectively. Generally speaking, the radionuclides most frequently found in all these types of sample are a) ¹³¹I, because of its use in thyroid disease treatment and its highly volatile nature, and b) ^{99m}Tc, due to its administration in radioaerosol form in diagnostic treatments. Other short

half-life emitters such as ¹⁸F, ²²³Ra and ¹³³Xe have also been determined in indoor air samples.

2.1. Indoor air samples

In the recent literature, one of the researchers' main concerns is the analysis of air samples from NM department work environments as part of internal dose assessment programmes. In general, the analytical procedures presented in published studies focusing on the quantification of different radionuclide activities in these samples are quite similar and commonly involve two steps: a) sample collection and b) measurement.

The most usual strategies applied for air collection to determine the most widely used medical radionuclides are based on active sampling (AS) (Brudecki et al., 2018; Carneiro et al., 2015; Damien et al., 2015; Ferdous et al., 2017; Ferrand et al., 2010; Hoi et al., 2017, 2016; Jiemwutthisak et al., 2012; Kopisch et al., 2011; Leners et al., 2011; Unpublished results, J. Martínez; Mietelski et al., 2005; Schomäcker et al., 2017), passive sampling (PS) (Jiménez et al., 2012; Mróz et al., 2018) and *in situ* monitoring (De Massimi et al., 2017; Giardina et al., 2015; Kawase et al., 2015; Suhariyono and Bunawas, 2015; Yamamoto et al., 2018).

In the case of AS, different filter media have been used depending mainly on the radionuclide to be determined. Regarding ¹³¹I, the selection of materials depends on the form in which this radionuclide is present in the air. Particulate filters are used to retain the elemental or different iodine compounds associated with the particles, while a wide range of solid adsorbent surfaces are used to trap ¹³¹I, such as gaseous molecular iodine, organic and inorganic compounds (Schomäcker et al., 2017). A review was recently published providing the main advantages and drawbacks of various porous materials used to extract the radioactive iodine present in air samples (Huve et al., 2018). Of the different materials used to collect the ¹³¹I present in indoor air samples, the most commonly used is activated charcoal (AC) (Brudecki et al., 2018; Carneiro et al., 2015; Damien et al., 2015; Hoi et al., 2017, 2016; Jiemwutthisak et al., 2012; Kopisch et al., 2011; Mietelski et al., 2005; Schomäcker et al., 2017). It has been reported that, due to its physical characteristics such as high surface area and pore volume and size (Nandanwar et al., 2016), AC is capable of retaining ¹³¹I gaseous fraction. Other impregnation substances have also been used to improve the adsorption capacity of this material (González-García et al., 2011; Gourani et al., 2014). González-García et al. (2011), for example, reported that triethylenediamine (TEDA) improves AC methyl iodide affinity by forming stable ammonium salts. In the case of ^{99m}Tc, the most commonly used filter materials are paper filters (Ferdous et al., 2017; Ferrand et al., 2010), borosilicate fibre filters (Unpublished results, J. Martínez) and HEPA H14 filters (Bombardier et al., 2012). The reported papers demonstrate that all these materials are capable of trapping 0.1–0.3 μm particles with an efficiency as high as 99% (Ferrand et al., 2010; Unpublished results, J. Martínez).

The active sampling collection methodologies also vary according to the operating flow rate applied. In this regard there are strategies based on low volume (LVS) and high volume samplers (HVS). The sampling approaches based on LVS are the most widely employed, and noteworthy in this group are personal air samplers and static air samplers (Fig. 1, a and b respectively) (Carneiro et al., 2015; Damien et al., 2015; Ferrand et al., 2010; Hoi et al., 2017, 2016; Jiemwutthisak et al., 2012; Kopisch et al., 2011; Leners et al., 2011; Unpublished results, J. Martínez; Schomäcker et al., 2017). In both cases researchers collect air samples at approximately 1.5 m above the floor to simulate the breathing zone (Brudecki et al., 2018; Ferrand et al., 2010; Hoi et al., 2017, 2016; Jiemwutthisak et al., 2012; Unpublished results, J. Martínez), following IAEA (1999) recommendations. Regarding personal air samplers (Fig. 1, a), these are usually used to collect representative samples of occupational inhaled air in order to estimate indi-

Table 2
A summary of reported analytical methods for determining medical radionuclides in indoor air samples.

Isotope	Sampling method		Detector	MDA	Sampling site	Activity concentration	Ref.		
	Type	Flow [m ³ /h]	Support	[Bq/m ³]		[Bq/m ³]			
¹³¹ I	AS - HVS	30	Whatman aerosol glass filter Charcoal filter impregnated with KI	HPGe	n.r.	Air above septic tank	0.748 ^a	Mietelski et al. (2005)	
		51	Paper filter	HPGe	n.r.	Hot laboratory	0.0163 ^b 0.0064 ^b	Ferdous et al. (2017)	
		30	Petryanov filter FPP-15-1.5 AC impregnated with KI	HPGe	n.r.	Hot room	492 ± 4 ^a	Brudecki et al. (2018)	
	AS - LVS	0.06	0.18	AC sandwich	HPGe	0.016 (Bq)	Radiopharmacy laboratory	7.2 ± 0.6 ^b 208 ± 3 ^a 8.5 ± 0.9 ^b 7.4 ^c	Carneiro et al. (2015)
				Carbon impregnated cellulose filters	3 × 3" NaI (TI)	0.18 (Bq)	Fume hood	31.6 ± 16 ^c	Jiemwutthisak et al. (2012)
		n.r.	2	2 × 2" NaI (TI)	Well counter	0.37 (Bq)	Therapy room	31.9 ± 22.3 ^c	
				Charcoal cartridge	Nal (TI)	n.r.	Preparation and administration room	2400 ^a	Kopisch et al. (2011)
		4.2	TEDA-AC cartridge	HPGe	n.r.	Patient room	73.15–7563.81 ^a	Damien et al. (2015)	
		4.2	TEDA-AC cartridge	HPGe	n.r.	Distilling, packing and processing and hot cell room	814.96 ± 37.18 ^a	Hoi et al. (2017)	
		4.2	TEDA-AC cartridge	HPGe	n.r.	Distilling room Packing room Hot cell room	2580 ± 1011.7 ^a 1986.5 ± 1754.7 ^a 726.4 ± 169.6 ^a	Hoi et al. (2016)	
	4.5	CP100 (TEDA-AC)	NaI (TI)	0.1	Exhaust air from laboratory	33.36·10 ⁶ (Bq) ^{c,d}	Schomäcker et al. (2017)		
	PS	–	–	GF50 (glass fiber filter) 2 BE110 (CdI ₂ on Chromorb-P) GY-130 (silver zeolite filter)	LSC	0.14	In-patient room	0.037–0.498 ^a	Jiménez et al. (2012)
				PicoRad™					
–		PicoRad™ with Petryanov filter	HPGe	n.r.	Dose preparation room Dose administration room Shielded cell Hot room	0.622 ^a 0.202 ^a 0.516 ^a 4.71 ± 0.82 (Bq) ^a	Mróz et al. (2018)		
Online monitoring		n.r.	–	Portable LaBr ₃	n.r.	Nurses station Radioisotope production stack	0.59 ± 0.36 (Bq) ^a 321.16	Suhariyono and Bunawas (2015)	
^{99m} Tc	AS - HVS	51	Paper filter	HPGe	n.r.	Hot laboratory	0.0042 ^c	Ferdous et al. (2017)	
	AS - LVS	n.r.	Paper filter AC cartridge	γ-spectrometry	n.r.	Administration room	4.6·10 ³	Ferrand et al. (2010)	
		n.r.	n.r.	γ-spectrometry	n.r.	Gammacamera room Dose administration room	1.5 7–191	Leners et al. (2011)	
	5.4	Borosilicate fibre filter	HPGe	0.028	Dose administration room	2.1·10 ⁵ –6.4·10 ⁵	(Unpublished results, J. Martínez)		
¹⁸ F	Online monitoring	n.r.	–	NaI(Tl) with shielding	n.r.	Hot wait room	360–1470 2.4·10 ⁴ –5.4·10 ⁴ Bq/m ³		
						Hot laboratory	137		
						Hall	129		
						Radiopharmacy laboratory	141 194	De Massimi et al. (2017)	

Table 2 (Continued)

Isotope	Sampling method		Detector	MDA	Sampling site	Activity concentration	Ref.
	Type	Flow [m ³ /h]					
²²³ Ra	Online monitoring	10	–	NaI(Tl) with shielding LaBr ₃ :Ce	n.r.	Radioisotope production stack	< 20 (Bq/L) Giardina et al. (2015)
		n.r.	–	Electrostatic collecting-type detector	n.r.	Imaging room	n.r. Yamamoto et al. (2018)
¹³³ Xe	Online monitoring	n.r.	–	CsI(Tl)	n.r.	Administration room	37 ± 2.1 µSv/h Kawase et al. (2015)

AS Active sampling.

HVS High volume sampler.

LVS Low volume sampler.

PS Passive sampling.

n.r. not reported.

^a ¹³¹I gaseous fraction.^b ¹³¹I aerosol fraction.^c ¹³¹I total activity.^d ¹³¹I organic fraction.

vidual ¹³¹I intake (European Commission, 2018), and the flow rates at which they usually operate are below 0.2 m³/h (Carneiro et al., 2015; Jiemwutthisak et al., 2012; Kopisch et al., 2011). Carneiro et al. (2015) recently used this type of sampler at a flow rate of 0.06 m³/h to collect air samples from above a hand-made AC sandwich filter in a radio-pharmacy laboratory which was capable of assessing the internal dose received due to the radionuclide inhalation mentioned earlier. In contrast, static air samplers (Fig. 1, b) working at flow rates of 2.0 m³/h and 4.2 m³/h are commonly used to monitor air conditions in the workplace (Damien et al., 2015; Hoi et al., 2017, 2016; Schomäcker et al., 2017). For example, LVS have been used by Schomäcker et al. (2017) as an effective tool for evaluating the ¹³¹I retention capability of fume hoods in NM facilities and for determining and distinguishing the ¹³¹I compounds present in air. Nowadays European standard EN 14175-4 (2004) tests the escape of hazardous agents from fume hoods, but the cited study suggests that, according to the air measurements taken, this standard is not sensitive enough to properly evaluate the protective function relating to radioactive iodine.

HVS (Fig. 1, c) has recently been introduced as a sampling methodology, working at flow rates of between approximately 30.0 m³/h and 50.0 m³/h (Brudecki et al., 2018; Ferdous et al., 2017). The main advantage of using HVS rather than LVS is the relatively short collection time involved, which enables a greater amount of air to be sampled, making it possible to take a considerable number of samples from different locations within a short period of time. However, LVS based methodologies are extensively used especially for the ease with which their equipment can be handled and for their portability compared to methodologies based on HVS.

As far as the detection system is concerned, various radiometric detectors have been used to quantify ^{99m}Tc and ¹³¹I on active sampling filter media, but the usual choice is gamma-ray spectrometry. High-purity germanium detectors (HPGe) are the most usual detection technique employed in the literature (Brudecki et al., 2018; Carneiro et al., 2015; Ferdous et al., 2017; Hoi et al., 2017, 2016; Unpublished results, J. Martínez; Mietelski et al., 2005). Thallium-activated sodium iodide crystals (NaI(Tl)) have been also used in some cases (Damien et al., 2015; Jiemwutthisak et al., 2012; Schomäcker et al., 2017). For both types, the filter media require minimum handling before measurement. In addition, the particulate filter and the solid adsorbent materials used for sampling can be measured together, as long as the aim of the measurement is to quantify the total ¹³¹I activity in air (Carneiro et al., 2015; Jiemwutthisak et al., 2012; Schomäcker et al., 2017).

However, other researchers prefer an independent measurement so as to be able to differentiate between and quantify the activity of various forms of ¹³¹I in the atmosphere through their specific adsorption in different materials (Brudecki et al., 2018; Ferdous et al., 2017; Hoi et al., 2017, 2016; Mietelski et al., 2005). Using these strategies, as can be observed in Table 2, a number of different authors in the literature have found the highest ¹³¹I activity concentration in the gaseous fraction (Brudecki et al., 2018; Mietelski et al., 2005). When comparing the results of the different studies in terms of activity concentrations there is much variability, which can be explained by differences in the NM departments themselves and their own particular ways of administering doses to patients, among other reasons. The presence of ¹³¹I in the air is high in places where high concentrations of this radionuclide are produced, handled and administered, as would be expected (Brudecki et al., 2018; Carneiro et al., 2015; Damien et al., 2015; Ferdous et al., 2017; Hoi et al., 2017, 2016; Jiemwutthisak et al., 2012). The activity concentrations found in these areas ranged from 32 Bq/m³ (Jiemwutthisak et al., 2012) to 7563.8 Bq/m³ (Damien et al., 2015). There is also a wide dispersion in the results for ^{99m}Tc in air samples, since each medical centre uses different doses and different tracer molecules. Generally speaking, the highest activity concentrations have been found in the administration room, where the radioaerosol is produced for *in situ* administration (Ferrand et al., 2010; Unpublished results, J. Martínez). Leners et al. (2011) found the presence of ^{99m}Tc here at levels of 7–191 Bq/m³ despite the application of protection measures such as portable filtration units installed above the patient and the use of FFP2 face masks by the patient and medical staff. Martínez et al. (Unpublished results) recently determined the occurrence of this radionuclide in other areas of an NM department such as the corridor and the gamma camera room at levels of 2.4·10⁴–5.4·10⁴ Bq/m³ and 360–1470 Bq/m³ respectively. This occurred during the performance of a diagnostic treatment when, due to the generation of a radioactive aerosol, it could have easily spread throughout the NM environment.

PS is an alternative sampling strategy used for determining radionuclides in air, i.e. ¹³¹I, and is another way of estimating this radionuclide's contribution to the effective occupational dose. There is a dearth of literature that uses this approach (Jiménez et al., 2012; Mróz et al., 2018) even though it has several advantages over AS insofar as it is a) cheaper, b) easy to handle, c) noise-free, d) unobtrusive while sampling, and e) requires no electrical current. Passive sampling is based on the deposition of the ¹³¹I present in indoor air onto AC, which can

Table 3
A summary of reported analytical methods for determining medical radionuclides in outdoor liquid samples.

Sample	Sampling method		Sample pretreatment	Detector	MDA [Bq/L]	Activity concentration		Ref.	
	Type of sample	Volume [L]				^{99m} Tc [Bq/L]	¹³¹ I [Bq/L]		
WWTP influent waters	24-h composed	1	Addition of cellulose powder	HPGe	n.r.	1.18–19.0	0.17–0.86	Fischer et al. (2009)	
	n.r.	n.r.	–	HPGe	n.r.	0.37–0.98	0.33–3.5	Chang et al. (2011)	
	Spot	1	Ag ¹³¹ I precipitation in acidic medium	LSC	0.011 (Bq/kg)		0.49–2.6 (Bq/kg)	Jiménez et al. (2011b)	
	Spot	1	Precipitation with NH ₄ OH	HPGe	0.06–0.08 (Bq/kg _{ww})		0.65 (Bq/kg _{ww})	Cosenza et al. (2015)	
	Spot	5	–	HPGe	0.030–0.1 (Marinelli)		5–10% AEI	Hormann and Fischer (2017)	
	Spot	5	2-step iodine extraction procedure: 1- organic fraction 2- inorganic fraction 3- residual iodine fraction	HPGe	0.002–0.015 (PMMA dish)		70% BEI	Fischer (2017)	
WWTP effluent waters	24-h composed	2	2. Vacuum filtering, Ag ¹³¹ I precipitation in acidic medium, using NaOH to increase pH	HPGe	0.004 (filters)		0.07–0.39	Martínez et al. (2018)	
	24-h composed	5	–	HPGe	0.2 ¹³¹ I 4.9 ^{99m} Tc	<5–50	<0.2–4.4	Mulas et al. (2019)	
	n.r.	4	–	BEGe	0.2		0.25	Smith et al. (2008)	
	24-h composed	1	Addition of cellulose powder	HPGe	n.r.	0.07–3.89	0.04–0.98	Fischer et al. (2009)	
	n.r.	–	–	HPGe	n.r.	< MDA	0.41–1.49	Chang et al. (2011)	
	Spot	1	Ag ¹³¹ I precipitation in acidic medium	LSC	0.011 (Bq/kg)		0.18–0.93 (Bq/kg)	Jiménez et al. (2011b)	
	24-h composed	–	Precipitation with NH ₄ OH	HPGe	0.1		< MDA - 4.7	Veliscek Carolan et al. (2011)	
	Grab	1	–	LEGe	1.7		1.8–217	Rose et al. (2012)	
	Spot	n.r.	Filtering by using 47 mm 0.7 µm glass fiber filter. Dry at 40 °C filters overnight	LEGe	50,000 (Bq/kg) ^c		2.5–227 ^a 61 - 2801 (Bq/g) ^c		
	Spot	1	Vacuum filter, 47 mm 0.7 µm glass fiber filter	LEGe	0.2		0.9–8.1 ^a	Rose et al. (2013)	
Hospital wastewater	Spot	1	–	HPGe	0.08–0.9 (Bq/kg _{ww})		0–0.17 (Bq/kg _{ww})	Cosenza et al. (2015)	
	Spot	5	2-step iodine extraction procedure: 1- organic fraction 2- inorganic fraction 3- residual iodine fraction	HPGe	0.030–0.1 (Marinelli)		70–80% AEI	Hormann and Fischer (2017)	
	24-h composed	0.8	–	HPGe	0.03		0.2–0.5	Montenero et al. (2017a)	
	24-h composed	5	–	HPGe	0.2 ¹³¹ I 4.9 ^{99m} Tc	<5–50	<0.2–4.4	Mulas et al. (2019)	
	24-h composed	–	Acidify with HCl until pH 2	HPGe	0.2	0.9–1789.9		Martínez et al. (2018)	
	Spot hourly	1	Addition of formaldehyde	HPGe	n.r.	6519		Krawczyk et al. (2013)	
	Surface water	Spot	500	Evaporation of 1 L Filter through a 0.45 µm filter cartridge	BEGe	50 (Bq/kg) ^c		3625 22 (Bq/kg) ^c	Smith et al. (2008)
		Spot	10	1. Decante 1 L and add H ₂ SO ₄ 2. Reduce by evaporation at 70 °C to 50 mL 3. Decante	HPGe	n.r.		0.2–1.4	Gilfillan and Timmers (2012)
		Spot	10	1. Evaporate sample volume < 100 °C 2. Rinse any residue with 2.5% HNO ₃ 3. Vacuum filter the sample	LEGe	0.03		0.08–6.07	Rose et al. (2013)
		Spot	180	Filter through 0.7 µm pore size filter	HPGe	1·10 ⁻⁴		4·10 ^{-3b}	Montenero et al. (2017a)
Spot		180	Addition of BioRad, filter Filter through 0.7 µm pore size filter Sequential series of BioRad addition and treatment with iron precipitate	HPGe	30 (Bq/kg) ^c 1.7·10 ^{-3d} n.r.		3·10 ^{-4c} 1.5·10 ⁻³ - 7.5·10 ⁻³ - 2·10 ⁻⁵ - 6.5·10 ⁻⁴	Montenero et al. (2017b)	

n.r. Not reported.

AEI iodine in organic fraction.

BEI iodine in inorganic fraction.

^a Filtered effluent.^b Dissolved.^c Suspended particulate material.^d Water column.**Table 4**

A summary of reported analytical methods for determining medical radionuclides in outdoor solid samples.

Sample	Sample pretreatment	Detector	MDA	Activity concentration		Ref.
				^{99m} Tc	¹³¹ I	
WWTP sludge	Addition of cellulose powder	HPGe	n.r.	138–6040 Bq/ Kg _{dw} ^a	11.8–574 Bq/Kg _{dw} ^a	Fischer et al. (2009)
	–	HPGe	26 Bq/kg	0.19–252 Bq/ Kg _{dw} ^b	0.14–201 Bq/Kg _{dw} ^b	Chang et al. (2011)
	Dry at 50 °C for 20 h and ground to fine powder	HPGe	n.r.	< MDA	203–231 Bq/kg ^b	Veliscek Carolan et al. (2011)
	Homogenisation and dry at 100 °C for 1 h	HPGe	0.1 Bq/kg	< MDA	1961–2410 Bq/kg ^c	Jiménez et al. (2011a)
	Dry at 130 °C, crushed and siefted	HPGe	67 Bq/kg _{dw}		8.1–45 Bq/kg _{ww} ^b	Camacho et al. (2012)
	–	LEGe	10–500 Bq/kg _{dw}		27 - 148,000 Bq/ kg _{dw} ^b	Rose and Swanson (2013)
	n.r.	HPGe	0.02–0.3 Bq/kg _{ww} ^e 0.06–0.3 Bq/kg _{ww} ^f 0.07–0.35 Bq/kg _{ww} ^c		12.3 Bq/kg _{ww} ^e n.r. 150 Bq/kg _{ww} ^c	Cosenza et al. (2015)
	Formaldehyde addition ^{a,b,h}	HPGe	0.2 Bq/L	119.6 Bq/L ^a 2.6 Bq/L ^g 3.4 Bq/L ^b	0.5–4.2 Bq/L ^a 4.2–28.7 Bq/L ^g 2.1–7 Bq/L ^b	Martínez et al. (2018)
	Dry at 100 °C, crushed in a ball mill and siefted in a 250 µm sieve ^c		1,1 Bq/kg ^c	n.d.	176.5–213.9 Bq/ kg _{dw} ^c	
	2-step iodine extraction procedure: 1 organic fraction	HPGe	0.030–0.1 Bq/L (Marinelli)	n.d.	AEI > BEI	Hormann and Fischer (2017)
	2 inorganic fraction		0.002–0.015 Bq/L (PMMA dish)			
	3 residual iodine fraction					
	2-step iodine extraction procedure: 1 organic fraction	HPGe	n.r.	n.d.	80% AEI and 10% BEI ^g	Martínez et al. (2019)
2 inorganic fraction				60% AEI and 20% BEI ^b		
3 residual iodine fraction						
Dehydrate ^c	HPGe	13 Bq/kg _{dw} ^{131Ia} 4 Bq/kg _{dw} ^{131Ic} 154 Bq/kg _{dw} ^{99mTc^a} 98 Bq/kg _{dw} ^{99mTc^c}	154–9530 Bq/ kg _{dw} ^a < MDA – 5000 Bq/kg _{dw} ^c	< MDA - 700 Bq/ kg _{dw} ^a 60–1000 Bq/kg _{dw} ^c	Mulas et al. (2019)	
Sediments	Dehydration and homogenization	HPGe	n.r.		202 - 1908 Bq/kg	Zannoni et al. (2019)
	–	BEGe	0.7 Bq/kg		3.3–6 Bq/kg	Smith et al. (2008)
	–	HPGe	n.r.		0.10–106 Bq/kg _{dw}	Fischer et al. (2009)
	–	HPGe	n.r.	< 0.3–1.6 Bq/kg ww	< 0.3–0.8 Bq/kg _{ww}	Malta et al. (2013)
Biota	Dry at 80 °C and homogenise using a mortar and pestle	LEGe	3.6 Bq/kg		1.3–117 Bq/L	Rose et al. (2013)
	Homogenize and still wet	HPGe	0.35 Bq/kg		n.d. - 68 Bq/m ²	Montenero et al. (2017a)
Biota	Algae: Unwash, patted dry and chopped	HPGe	0.039 Bq/kg _{ww}		0.37 ± 0.010 Bq/ kg _{ww}	Morita et al. (2010)
	Carp entrails	HPGe	n.r.		9–11 Bq/kg	Gilfillan and Timmers (2012)
	Mussels: Separate tissue from shells; muscle, liver and gonads	HPGe	n.r.	n.d. - 5 Bq/kg	n.d. - 12 Bq/kg	Malta et al. (2013)
	Mullets: Dry, homogenize			n.d. - 20 Bq/kg	n.d.	
	Algae: Dry at 50 °C for 20 h	HPGe	n.r.		1.2–73 Bq/kg _{ww}	Veliscek Carolan et al. (2011)
	Ground to fine powder					
Algae: Fresh analysed	HPGe	0.4 Bq/kg		n. d. - 91 Bq/kg _{dw}	Montenero et al. (2017a)	

^a Primary sludge.^b Digested sludge.^c Dewatered sludge.^e Mixed liquor.^f Recycled sludge.^g Secondary sludge.




Fig. 1. Active sampling equipment. a) Personal air sampler. Reproduced from (Jiemwutthisak et al., 2012); b) Static air sampler. Personal image; c) High volume sampler. Reproduced from the open access study (Brudecki et al., 2018) (<http://creativecommons.org/licenses/by/4.0/>).




Fig. 2. Examples of continuous air sampling systems. a) Air sample pumped through a Marinelli beaker externally coupled to a scintillation detector. Reproduced permission from (De Massimi et al., 2017), Copyright 2017, Elsevier; b) ^{222}Rn detector and ^{222}Rn and ^{219}Rn daughter detectors. Reproduced from the open access study (Yamamoto et al., 2018) (<http://creativecommons.org/licenses/by/4.0/>).

be contained in commercial PicoRad™ canisters (commonly used for ^{222}Rn collection) (Jiménez et al., 2012). Recently a pilot study performed by Mróz et al. (2018) tried to increase the affinity of AC for radioactive iodine species by impregnating the porous surface with KI or NaOH, since they expected that trapping efficiency would be improved with these reagents. However, the authors reported that further work needed to be done in this area because the strategy was unsuccessful due to an unexpected reduction in the AC active surface.

One of the major drawbacks of these two studies is that the canisters are exposed for a lengthy time, which varies from three days (Jiménez et al., 2012) to one week (Mróz et al., 2018). The results obtained represent time-weighted average concentrations. With this sampling approach it is not possible to detect ^{131}I activity concentration fluctuations in indoor air samples during the sampling time. The determination of this radionuclide in PS supports has been performed using the liquid scintillation technique (LSC) (Jiménez et al., 2012) and by HPGe (Mróz et al., 2018).

Continuous air sampling systems have also recently been used in the literature to monitor specific radionuclides such as ^{131}I (Suhariyono and Bunawas, 2015), ^{18}F (De Massimi et al., 2017; Giardina et al., 2015), ^{223}Ra (Yamamoto et al., 2018) and ^{133}Xe (Kawase et al., 2015). Using this strategy and depending on the detector, it is possible to obtain the radionuclide activity levels or air dose rates in real time. Continuous air sampling has a number of advantages over active and passive sampling. The sample collection and measurement steps are per-

formed together, for instance, and the system can be managed with a laptop computer or even a smartphone. Moreover, the determination of short half-life emitters can be performed accurately using easy-to-handle equipment that can operate for long periods of time. Thus, continuous measurement can provide real time information about activity fluctuations and possible incidences of high peak activity. This sampling strategy has been applied in the literature for different purposes. One of the *in situ* monitoring applications, as illustrated in Fig. 2 a, is to detect the presence of ^{18}F in the work environment of an NM department and assess occupational exposure (De Massimi et al., 2017). Another purpose is to monitor the stack emissions of ^{131}I and ^{18}F in production centres (Giardina et al., 2015; Suhariyono and Bunawas, 2015). In all these three studies, the methods presented are quite similar, involving pumping the air sample continuously through a Marinelli beaker (shielded or not) externally coupled to a scintillation detector such as NaI(Tl) or lanthanum bromide (LaBr_3), the latter having a better resolution. The study by Suhariyono and Bunawas (2015) compared the continuous air measurements of ^{131}I present in air from a stack following an active sampling strategy using an LVS equipped with a paper filter and AC cartridges. They concluded that the continuous air sampling approach can be used instead of active sampling because it is accurate, provides immediate results, and is portable and easy to operate. However, the continuous strategy cannot distinguish the ^{131}I compounds (i.e. $\text{CH}_3^{131}\text{I}$, $^{131}\text{I}_2$ or HO^{131}I) present in the sample because of the lack of any filter media in the system to trap these separately.

Table 5
A summary of reported analytical methods for determining medical radionuclides in biological samples.

Sample	Isotope	Sampling method	Sample pretreatment	Detector	MDA	Activity concentration	Ref.	
Urine	¹³¹ I	Spot sample	Store at 4 °C until measure Homogenization and determination of initial volume.	NaI	72 Bq/L	n.d.	Shoji et al. (2007)	
		24-h sample		HPGe	0.48–2.21 Bq/L	1.2 ± 0.1–105 ± 1 Bq/L		Lucena et al. (2007)
		Spot sample		–	HPGe	4.8 Bq/kg	5045 ± 45 Bq/kg maximum activity	Jeong et al. (2011)
		Spot sample	–	HPGe	–	6.47 ± 0.03 Bq/L – 283 ± 0.27 Bq/L	Ferdous et al. (2012)	
		24-h sample	–	HPGe	0.1 Bq	n. r.	Bitar et al. (2013)	
		Spot sample	–	HPGe	n. r.	5.78 ± 0.86 Bq/L - 389.95 ± 11.0 Bq/L	Ferdous (2016)	
		n.r.	–	HPGe	0.047 Bq/L	–	Bitar et al. (2016)	
		24-h sample	Addition of 10% (v/v) concentrated HNO ₃	NaI	0.88 Bq	0.37 ± 0.09 Bq/L	Peekhunthod et al. (2017)	
		Spot sample	–	HPGe	0.05–0.86 Bq	–	–	
		–	–	NaI (TI)	1.7 Bq	n. r.	Matheoud et al. (2018)	
		48 h post incorporation	–	Gammacamera	272 Bq ^a	n. r.	Rodríguez-Laguna et al. (2010)	
		48 h post incorporation	–	Gammacamera	852 Bq ^a	n. r.	Dfáz-Londoño et al. (2017)	
		Spot samples	–	HPGe	n.r.	17–574 Bq/d	Kim et al. (2018)	
		^{99m} Tc	Spot sample	–	HPGe	HPGe	8.58 ± 0.03 Bq/L - 314 ± 1.92 Bq/L	Ferdous et al. (2012)
			n.r.	–	HPGe	0.14 Bq/L	–	Bitar et al. (2016)
Spot sample	–		HPGe	n. r.	24.47 ± 2.14 Bq/L - 1529.5 ± 36.5 Bq/L	Ferdous (2016)		
Spot samples	–		HPGe	3 Bq/L	279.3 ± 80.4–18,652.4 ± 1218.7 Bq/L	(Unpublished results, J. Martínez)		
24-h sample	–		NaI (TI)	1 Bq/L	- 2100 Bq/d	–		
Spot sample	–		NaI (TI)	1 Bq	–	Matheoud et al. (2018)		
¹⁸ F	Spot sample		–	HPGe	0.0270–0.0580 Bq/g	0.138 ± 0.007 Bq/g –1.472 ± 0.027 Bq/g	Noh et al. (2016)	
	⁹⁹ Tc		n.r.	Evaporation and TEVA disk filtration	LSC	n.r.	n.r.	Eichrom Technologies (2014)
			n.r.	SPE TEVA resin automatic LOV	LSC	1 Bq/L	n.r.	Villar et al. (2013)
			n.r.	Reduction of salt effect Automatic DLLME	LSC	21 Bq/L	n.r.	Villar et al. (2015)
		n.r.	Filtration: 0.45 µm syringe filter	LSC	0.023 Bq	n.r.	Khan and Um (2015)	
n.r.		Colour removal PSr with Aliquat® 336	LSC	0.0036 Bq	n.r.	Barrera et al. (2016)		
Skin	¹³¹ I	Wipe with alcohol 10 cm ² of surface	–	Thyroid uptake probe	n. r.	103 Bq/cm ² front skin	Hamizah et al. (2012)	
		Wipe with alcohol 10 cm ² of surface	–	HGPe	n. r.	214 Bq/cm ² palm skin 125 Bq/cm ² hand	Guillot et al. (2016)	
Saliva	¹³¹ I	Salivette [®]	–	Activimeter	n. r.	< 50 Bq/cm ² other parts in order of MBq/g	Guillot et al. (2016)	
Urine	¹³¹ I	Spot sample	–	Well counter	n. r.	2928 ± 124 MBq	Demir et al. (2013)	
Exhaled breath	¹³¹ I	AS - LVS	–	γ-spectrometry	–	10 kBq/m ^{3a} (after 24 h)	Gründel et al. (2008)	
		Aerosol filter 2 stages of DSM 11 2 layers of AC AS - LVS GF50 (borosilicate fibre) BE110 (CdI ₂ on Chromorb-P) CP100 (TEDA on animal charcoal)	NaI (TI)	–	1–90 kBq/m ³ (after 1 h)	Schomäcker et al. (2011)		

n.r. Not reported.

AS - LVS Active sampling - low volume sampler.

^a MDA for 1.6L of urine.

Other specific continuous sampling approaches have also been applied. For instance, an electrostatic collecting-type detector was used to detect the alpha emitter daughter radionuclides of ¹¹⁹Rn in air samples

when ²²³Ra is used therapeutically (Yamamoto et al., 2018) (Fig. 2, b). Another interesting strategy found in the literature is based on the determination of *in situ* dose rates. This method was applied during ¹³³Xe




Fig. 3. Approaches for determining ^{99}Tc in urine samples. a) Lab-on-valve system with TEVA integrated column. Reproduced with permission from (Villar et al., 2013). Copyright 2013, American Chemical Society; b) Plastic scintillation resin approach with PSr cartridge. Reproduced with permission from (Barrera et al., 2016). Copyright 2016, Elsevier B. V.




Fig. 4. ^{131}I collection strategies for exhaled air from treated patients. a) Composition of a modular support system. Reproduced with permission from (Gründel et al., 2008). Copyright 2007, Oxford University Press; b) Illustration of a collection strategy. Reproduced from the open access study (Schomäcker et al., 2011) (<http://creativecommons.org/licenses/by/4.0/>).

administration in a lung-ventilation scintigraphy by employing a thallium-activated caesium iodide detector CsI(Tl) equipped with a module to convert the signal to dose equivalent (Kawase et al., 2015). The results of the applied strategy, expressed as air exposure dose levels, provide useful information to guarantee the safety of the patient and medical staff.

2.2. Outdoor samples

The administration of radiopharmaceuticals as unsealed sources in NM means the generation of radioactive effluents that reach the general sewage system, commonly discharged by one of two ways: a) from out-patients who release the excreta from home, and b) from their administration and use in medical centres whether or not they have radioactive decay tanks (Barquero et al., 2008b; Krawczyk et al., 2013). From these points the radioactive effluents can reach WWTP facilities. Once there, some radionuclides may be retained in the generated sludge, while others may be expelled into the environment (Martínez et al., 2018; Mulas et al., 2019; Palomo et al., 2010). In spite of the current good practices applied involving the reduction or elimination of radioactive waste from hospital effluents (Banerjee and Mitra, 2013; Rodríguez, 2012; Sudbrock et al., 2017), various studies have detected the presence of medical radionuclides in environmental samples from

the areas surrounding medical centres (Punt et al., 2007; Sundell-Bergman et al., 2008). These samples can be classified according to their physical state as a) liquid samples such as hospital wastewater, WWTP influent and effluent waters and surface water, and b) solid samples such as WWTP sludge, sediments and biota.

In the studies reviewed, the approaches aimed at determining different radionuclides, mainly ^{131}I and $^{99\text{m}}\text{Tc}$, in liquid samples generally involve three steps: a) sample collection, b) sample pretreatment, and c) measurement.

The collection of liquid samples is usually performed using polyethylene containers and the sample type may vary depending on the aim of the study: a) 24-h composed samples, which enable the total activity discharged during a day to be studied (Fischer et al., 2009; Martínez et al., 2018; Montenero et al., 2017a; Velisek Carolan et al., 2011), or b) spot samples, which give an idea of the activity released at a particular point in time (Cosenza et al., 2015; Gilfillan and Timmers, 2012; Hormann and Fischer, 2017; Jiménez et al., 2011b; Krawczyk et al., 2013; Malta et al., 2013; Montenero et al., 2017a, 2017b, Rose et al., 2013, 2012). In general terms, liquid samples can be classified according to their activity concentration levels. Samples such as WWTP influent and effluent waters and hospital wastewater are directly influenced by the radioactive source (discharges from out-patients and medical centres) and usually have high activity concentration levels.

Studies reported in the literature, as shown in Table 3, have presented activity levels ranging from a) 0.07 Bq/L to 4.4 Bq/L in WWTP influent waters, and b) 0.14–217.0 Bq/L in WWTP effluent waters, to c) about 3625.0 Bq/L in hospital wastewater. These samples are not usually subject to pretreatment, although sometimes just a simple one is involved in the reported strategies (Chang et al., 2011; Cosenza et al., 2015; Fischer et al., 2009; Krawczyk et al., 2013; Martínez et al., 2018; Montenero et al., 2017a; Mulas et al., 2019; Rose et al., 2013, 2012; Smith et al., 2008; Veliscek Carolan et al., 2011). For example, Rose et al. (2012) filtered 1 L of WWTP effluent water through a 0.7 μm glass fibre filter, but this pretreatment showed no differences in terms of activity concentrations between the results obtained from the direct gamma-ray spectrometry measurement of the sample, from measurement of the filtered sample and from measurement of the filter used. In those cases reported by Jiménez et al. (2011b) and Martínez et al. (2018), other pretreatments based on silver iodide (AgI) precipitation are applied when the activity concentrations of WWTP effluent waters are in the low range of the corresponding presented levels. These procedures are based on chemical treatment of the sample presented by Baeza et al. (2004) and in UNE-EN ISO 10703 (AENOR, 2016), with some modifications made so as to optimize the measurement time by LSC counting (Jiménez et al., 2011b) and to selectively separate ^{131}I from other radionuclides measured in a filter geometry using HPGe (Martínez et al., 2018). Other pretreatments are based on the flocculation strategies used in another study from the literature aimed at predicting the ^{131}I dynamics and behaviour in the different WWTP compartments (Hormann and Fischer, 2017). To this end, the procedure consisted of relating the radioactive iodine content to a) the WWTP influent organic fraction, by using aluminium chloride based flocculant, b) the inorganic fraction, by precipitating ^{131}I as silver iodide, and c) the residual fraction.

In the case of surface water samples, activity concentration levels are usually lower than for WWTP samples and hospital wastewater, in the range of $2\cdot 10^{-5}$ Bq/L to 6.7 Bq/L. Hence the general strategy when analysing these samples includes as a pretreatment, as reported by various authors, a sample preconcentration based on a variety of approaches including evaporation or the use of anionic resins, among others (Gilfillan and Timmers, 2012; Montenero et al., 2017a, 2017b; Rose et al., 2013; Smith et al., 2008). Montenero et al. (2017a), for instance, present a method in which a BioRad AG 1-X8 anionic exchange resin was added to 180 L of surface water samples in order to trap the ^{131}I . The authors take advantage of the presence of this radionuclide in WWTP effluent water to trace it in a large lake sample (Montenero et al., 2017a).

As regards detection techniques, HPGe is the most widely used radiometric detector for quantifying ^{131}I and $^{99\text{m}}\text{Tc}$ in liquid samples (Chang et al., 2011; Cosenza et al., 2015; Fischer et al., 2009; Gilfillan and Timmers, 2012; Hormann and Fischer, 2017; Krawczyk et al., 2013; Malta et al., 2013; Martínez et al., 2018; Montenero et al., 2017a, 2017b; Mulas et al., 2019; Veliscek Carolan et al., 2011), although low energy germanium detectors (LEGe) (Rose et al., 2013, 2012) and broad energy germanium detectors (BEGe) (Smith et al., 2008) have also been used. In some cases LSC has also been used for determining ^{131}I content in WWTP influent and effluent water samples (Jiménez et al., 2011b).

Of all the liquid samples of this type measured in studies in the literature, hospital wastewater is the sample with the highest activities, as expected, achieving maximum values of 1789.9 Bq/L (Martínez et al., 2018) and 6519.0 Bq/L (Krawczyk et al., 2013) for $^{99\text{m}}\text{Tc}$ and 3625.0 Bq/L for ^{131}I . Almost all of these studies have focused on spot samples (Cosenza et al., 2015; Gilfillan and Timmers, 2012; Hormann and Fischer, 2017; Jiménez et al., 2011b; Krawczyk et al., 2013; Montenero et al., 2017a, 2017b; Rose et al., 2013; Smith et al., 2008). ^{131}I has generally been found in influent WWTP samples with

activity concentrations ranging from 0.07 Bq/L (Martínez et al., 2018) to 2.6 Bq/L (Jiménez et al., 2011b). This variation in the activities obtained could be due to a number of factors, as Mulas et al. (2019) report in their study. These authors concluded from their results that “activities found in the studies carried out in urban areas, where hospitals were equipped with abatement systems, showed a one-order-of-magnitude lower range where abatement systems are not used”. In the same study, the presence of other NM radionuclides such as $^{99\text{m}}\text{Tc}$ and ^{123}I was also confirmed. There has also been much interest in the literature in determining medical radionuclides in WWTP effluent water samples and surface waters. Activity levels of few Bq/L have been found in such samples (Chang et al., 2011; Cosenza et al., 2015; Fischer et al., 2009; Gilfillan and Timmers, 2012; Jiménez et al., 2011b; Malta et al., 2013; Montenero et al., 2017a, 2017b; Mulas et al., 2019; Rose et al., 2012, 2013; Smith et al., 2008; Veliscek Carolan et al., 2011), as in the study by Cosenza et al., for example, in which the ^{131}I activity concentrations in WWTP effluent samples ranged between 0 and 0.17 Bq/kg_{ww} in the course of a long-term sampling campaign (Cosenza et al., 2015).

As previously mentioned, solid samples can also be influenced by NM departments. In particular, radionuclides can be found in a) WWTP sludge, since this sample may tend to concentrate the radioisotopes present in the influent water due to the facility's processes, and b) sediments and biota, due to the transference of radioisotopes between the aquatic media and these samples. The collection of these types of sample is usually performed using polyethylene containers. The literature includes several alternative proposals for these kinds of solid sample as pretreatment, although in some cases different authors have preferred direct measurement (Chang et al., 2011; Fischer et al., 2009; Gilfillan and Timmers, 2012; Malta et al., 2013; Martínez et al., 2018; Mulas et al., 2019; Rose and Swanson, 2013). Of the different approaches used as pretreatment, the usual choices generally involve drying, sieving and homogenizing the sample (Camacho et al., 2012; Jiménez et al., 2011a; Martínez et al., 2018; Montenero et al., 2017a; Morita et al., 2010; Veliscek Carolan et al., 2011; Zannoni et al., 2019). However, some of these treatment procedures have certain operational requirements, such as drying the sample, and in this case the temperature applied can be dramatic as regards the determination of ^{131}I , since this radionuclide can undergo a volatilization process (Gilfillan and Timmers, 2012; Montenero et al., 2017a; Rose et al., 2012). The highest value found in the literature which ensures the preservation of this radioisotope in a sludge sample after drying is around 100 °C (Sundell-Bergman et al., 2009). Other studies in the literature, such as those by Hormann and Fischer (2017) and Martínez et al. (2019), aim to qualitatively evaluate the behaviour of ^{131}I in the different compartments of a WWTP. The procedures are mainly based on isolating the radioactive iodine content present in three fractions (organic, inorganic and residual) of the different kinds of generated sludge by using flocculants and chemical precipitation in the form of silver iodide. Both the studies mentioned related their results to the WWTP processes, concluding that a) the ^{131}I present in the secondary sludge is associated mainly with the organic fraction (particles, colloids and organic matter) due to the microbiological process involved in the aeration tank, and b) the presence of ^{131}I in the digested sludge organic fraction diminished, probably due to oxidation of the organic matter brought about by anaerobic microorganisms.

Concerning detection systems, HPGe is the radiometric detector most frequently used to quantify ^{131}I and $^{99\text{m}}\text{Tc}$ in solid samples (Camacho et al., 2012; Chang et al., 2011; Cosenza et al., 2015; Fischer et al., 2009; Gilfillan and Timmers, 2012; Hormann and Fischer, 2017; Jiménez et al., 2011a; Malta et al., 2013; Martínez et al., 2019, 2018; Montenero et al., 2017a; Morita et al., 2010; Mulas et al., 2019; Veliscek Carolan et al., 2011; Zannoni et al., 2019), although LEGe (Rose et al., 2013; Rose and Swanson, 2013) and BEGe (Smith et al.,

2008) have also been used. The presence of these two radionuclides – and to a lesser extent others such as ^{67}Ga , ^{111}In and ^{123}I – in WWTP sludge samples is common in almost all the studies reviewed. ^{131}I has been found in a wide range of activity values in different WWTP sludges, ranging from 0.14 Bq/kg_{dw} (dry weight) to 148000 Bq/kg_{dw} (Camacho et al., 2012; Chang et al., 2011; Cosenza et al., 2015; Fischer et al., 2009; Hormann and Fischer, 2017; Jiménez et al., 2011a; Martínez et al., 2019, 2018; Mulas et al., 2019; Rose and Swanson, 2013; Velisek Carolan et al., 2011; Zannoni et al., 2019). Activated sludge is the WWTP sludge type that tends to accumulate the highest activity levels of this radionuclide, mainly due to microorganism action during the previous biological treatment and interactions with organic matter (Cosenza et al., 2015; Hormann and Fischer, 2017; Kaplan et al., 2014; Martínez et al., 2019, 2018; Mulas et al., 2019). The radionuclide accumulation in sludge due to the settlement of particles or microbiological treatment is generally thought also to be governed by factors related to the WWTP facility, such as a) the time the wastewater takes to reach the WWTP, b) the population equivalents, c) the hydraulic retention time, and d) the age of the sludge (Mulas et al., 2019; Zannoni et al., 2019). In spite of the high activity concentrations found in this type of sample, the authors conclude that its handling and land use pose no occupational radiological risk (Cosenza et al., 2015; Jiménez et al., 2011a; Martínez et al., 2018; Mulas et al., 2019; Zannoni et al., 2019).

Since the removal of medical radionuclides in WWTP facilities is incomplete (Mulas et al., 2019), they have also been found in sediments and biota at a variety of lower activity levels ranging from <0.3 Bq/kg_{sw} to 73 Bq/kg_{sw} (Malta et al., 2013; Velisek Carolan et al., 2011). The determination of ^{131}I in these samples is today used to trace WWTP radioactive effluent in the aquatic environment. For example, there are different species of marine alga that are capable of concentrating this radionuclide, and these can therefore be used as biomonitoring organisms of ^{131}I levels (Morita et al., 2010; Velisek Carolan et al., 2011).

3. Biological samples: radioanalytical methods

Both NM workers and the general public can be radiologically exposed due to the presence of medical radionuclides in the NM department environment. In recent years the individual monitoring of these people to detect any radionuclide intake has been an issue of concern. Although the use of *in vivo* measurements (i.e. whole body counting or thyroid counting (Bitar et al., 2016)) is recommended for almost all short half-life radionuclides, the analysis of biological samples from these individuals is also important to complement the previous information and is useful for estimating internal occupational exposure (ISO, 2016).

Patients undergoing NM treatment can also act as radioactive sources, exposing caregivers and family members (Uhrhan et al., 2014), and therefore any protective measures that may have been taken by these people could be assessed by analysing the patients' body fluids.

The most frequently analysed biological sample in the reviewed studies is generally urine, since it is one of the main radionuclide excretion pathways from the human body and sample collection is easy and non-invasive (Hou, 2011; International Atomic Energy Agency (IAEA), 2009). Urine-based measurements have been commonly used as a) a screening method, b) when *in vivo* measurements cannot be performed, c) to verify possible internal contamination, and d) after a supposed accidental intake (Bitar et al., 2013; Breustedt et al., 2018). According to the literature, the radionuclides most usually found in urine samples are a) ^{18}F (Noh et al., 2016), $^{99\text{m}}\text{Tc}$ (Bitar et al., 2016; Ferdous, 2016; Ferdous et al., 2012; Unpublished results, J. Martínez; Matheoud et al., 2018) and ^{131}I (Bitar et al., 2016, 2013; Díaz-Londoño et al.,

2017; Ferdous, 2016; Ferdous et al., 2012; Happel et al., 2013; Jeong et al., 2011; Kim et al., 2018; Lucena et al., 2007; Matheoud et al., 2018; Peekhunthod et al., 2017; Rodríguez-Laguna et al., 2010; Shoji et al., 2007) from exposed workers, and b) $^{99\text{m}}\text{Tc}$ (Barrera et al., 2016; Eichrom Technologies, 2014; Khan and Um, 2015; Villar et al., 2015, 2013) and ^{131}I (Demir et al., 2013) from treated patients. In addition, ^{131}I is also excreted in saliva, sweat and in air exhaled by the patient (Gründel et al., 2008; Guillot et al., 2016; Hamzah et al., 2012; International Atomic Energy Agency (IAEA), 2009; Schomäcker et al., 2011). So far, however, these patient samples have been investigated in very few studies, although the results obtained should be taken into consideration since they may provide valuable information as regards setting radiation safety precautions.

The following sections (3.1 and 3.2) contain a discussion of the different approaches found in the recent literature for determining different medical radionuclides in biological samples. A selection of the most significant studies is given in Table 5, which includes details of the collection, pretreatment and measurement strategies commonly used for biological samples, along with the radiological content in terms of activity concentrations of the different radionuclides found in the samples.

3.1. Biological samples from NM workers

The analysis of biological samples, mainly urine, from workers involves individual internal monitoring, the results of which provide information about a) estimated intake, by using the corresponding biokinetic model, and b) the corresponding committed effective dose (Breustedt et al., 2018). ISO 20553 (2006) sets out the need to perform this assessment on those workers who are exposed and receive a relevant dose from unsealed radionuclide intake that is equal to or greater than 6 mSv (Bingham and Etherington, 2018).

The most commonly used bioassays in the literature involve similar steps: a) sample collection, and b) measurement.

The collection of urine samples is a crucial step and there are three important factors to consider, as recommended in the report on the *Medical monitoring of occupational internal exposure to radionuclides in nuclear installations* (French Occupational Health Medicine Society, 2011): a) it should be carried out in uncontaminated areas to avoid sample contamination, b) the volume of the sample should be recorded, and c) the total activity should be assessed per unit of time from the provided sample. In this regard, ISO 16637:2016 (2016) recommends the collection of 24-h urine samples in order to carry out an accurate dose assessment based on daily excretion. Some of the studies reviewed do indeed apply this recommendation (Happel et al., 2013; Lucena et al., 2007; Unpublished results, J. Martínez; Peekhunthod et al., 2017). However, mainly due to technical considerations this practice is not usually carried out and the usual procedure is to collect spot samples (Bitar et al., 2016, 2013; Ferdous, 2016; Ferdous et al., 2012; Unpublished results, J. Martínez; Matheoud et al., 2018; Noh et al., 2016; Shoji et al., 2007). This provides valuable information as regards internal occupational contamination at a particular point in time. These urine samples are commonly taken three to 4 h after handling the relevant radionuclide or once a month, depending on the radionuclide and the aim of the monitoring study. The results obtained, in terms of activity concentrations, are not representative of the whole radionuclide intake, and therefore the specific radionuclide activity needs to be normalized. Two common normalization methods are used for this purpose by the different authors: a) by creatinine content, or b) by volume (European Commission, 2018; Paquet et al., 2015). However, an interesting study published recently by Noh et al. (2016) used urine spot samples without normalization. The main advantage of this procedure is that it is hoped it will serve to monitor internal occupational exposure to ^{18}F and other short half-life radionuclides by using

in vitro bioassay methodology and the newly developed biokinetic models, thereby avoiding the task of sample normalization.

Measurement methods are generally based on gamma-ray spectrometry, which is used to detect ^{131}I , $^{99\text{m}}\text{Tc}$ and ^{18}F in urine samples, and a positive aspect of this is that no pretreatment is needed (Bitar et al., 2016; Díaz-Londoño et al., 2017; Ferdous, 2016; Ferdous et al., 2012; Jeong et al., 2011; Kim et al., 2018; Matheoud et al., 2018; Rodríguez-Laguna et al., 2010; Shoji et al., 2007). However, some studies in the literature have applied homogenization and acidification with nitric acid to minimize precipitation and prevent bacterial growth (Peekhunthod et al., 2017). The HPGe detector (Bitar et al., 2016, 2013; Ferdous, 2016; Ferdous et al., 2012; Jeong et al., 2011; Lucena et al., 2007; Unpublished results, J. Martínez; Noh et al., 2016; Peekhunthod et al., 2017) is the preferred choice, although the NaI scintillator detector has also been employed (Matheoud et al., 2018; Peekhunthod et al., 2017). In a novel approach, Díaz-Londoño et al., 2017 and Rodríguez-Laguna et al. (2010) took advantage of the gamma cameras present in NM departments to quantify the radionuclide activities of workers' urine samples and to self-assess internal occupational exposure. Both studies used this equipment without the presence of collimators so as to achieve maximum sensitivity and were able to achieve detection of the annual effective dose limit of 1 mSv. This measurement approach is also advantageous because samples can be analysed *in situ*, meaning they do not need to be sent to external laboratories, thus reducing analysis time.

^{18}F , $^{99\text{m}}\text{Tc}$ and ^{131}I have been found in various studies in which NM workers' urine has been analysed. In these studies ^{131}I activity levels vary greatly between workers, ranging from 1.2 Bq/L (Lucena et al., 2007) to a maximum of 390.0 Bq/L (Ferdous, 2016). This variability in terms of ^{131}I activity concentrations depends on a number of aspects including the radionuclide activity administered, the protection measures undertaken and on the rate of urine excretion, which varies between individuals (Kim and Whang, 2009), among others. Studies into $^{99\text{m}}\text{Tc}$ in urine also illustrate this variability in their results, which range from 8.6 Bq/L (Ferdous et al., 2012) to 18652.0 Bq/L (Unpublished results, J. Martínez). Martínez et al. (Unpublished results), for example, evaluated $^{99\text{m}}\text{Tc}$ activity in different NM workers performing different tasks in an NM department. They concluded that those NM nurses involved in the $^{99\text{m}}\text{Tc}$ -based diagnostic study who were present when the radionuclide activity in air reached its maximum presented the highest $^{99\text{m}}\text{Tc}$ activity in 24-h urine samples, as expected.

3.2. Biological samples from treated patients

Those patients undergoing exposure due to medical diagnosis or treatments are in themselves a potential radioactive source. In this regard, a patient's body fluids may cause radiological impact on a) the environment, due to the discharge of radioactive urine and faeces, mainly $^{99\text{m}}\text{Tc}$, into the sewage system, and b) caregivers, medical staff and the general public, due to their exposure to the ^{131}I present in the patient's urine, saliva, sweat or exhaled air.

$^{99\text{m}}\text{Tc}$ is used in approximately 80% of the diagnostic studies performed worldwide. This short half-life radionuclide decays to ^{99}Tc , which has a long half-life ($T_{1/2} = 2.13 \cdot 10^5$ years) and high mobility in the environment (Barrera et al., 2016; Clases et al., 2018). The reviewed studies from the literature focus on the presence of $^{99\text{m}}\text{Tc}$ in patients' urine. Since $^{99\text{m}}\text{Tc}$ is a beta emitter, the radioanalytical methods used commonly involve a pretreatment step to isolate it from the matrix before measurement (Barrera et al., 2016; Eichrom Technologies, 2014; Khan and Um, 2015; Villar et al., 2015, 2013). Eichrom Technologies present a procedure based on the use of an extraction chromatographic resin for $^{99\text{m}}\text{Tc}$ separation – TEVA resin in disk format (Eichrom Technologies, 2014) – but it is a manual strategy and time-consuming. With the aim of overcoming the drawbacks associated

with such an approach, several attempts based on flow analysis techniques have appeared in recent literature, and these have been used to automate the strategies to provide faster, greener methods and improve the analyst's safety (Villar et al., 2015, 2013). In this regard it is important to highlight that a review setting out and comparing the most frequently used automated extraction and preconcentration strategies has been published (Rodríguez et al., 2016). There are various studies that use these types of automated tools for $^{99\text{m}}\text{Tc}$ determination in urine samples, such as the two reported by Villar et al. (2015, 2013). In the first of these the authors combined a solid phase extraction (SPE) based on TEVA resin with a lab-on-valve system (Fig. 3, a) (Villar et al., 2013) to isolate and preconcentrate the radionuclide. In order to avoid backpressure problems due to SPE, the second study was based on lab-in-syringe dispersive liquid-liquid microextraction (DLLME) (Villar et al., 2015). This study critically tested and discussed extractants and dispersers for DLLME, concluding that the optimal extractant was Aliquat[®]336 due to its high $^{99\text{m}}\text{Tc}$ extraction efficiency, while the best dispersant was acetone due to its cheapness and the fact that it provides higher reproducibility than others.

Barrera et al. (2016) (Fig. 3, b) recently presented an approach based on the use of plastic scintillation resins (PSr), a strategy that unifies the radionuclide separation and the scintillation measurement, thus reducing analysis time, sample handling and reagent consumption. In the case of $^{99\text{m}}\text{Tc}$ isolation, the PSr employed was a combination of plastic scintillation microspheres with Aliquat[®] 336 as the extractant, which also acts as a scintillator agent reducing the generation of organic waste. Although this is not a novel methodology, further research into the subject would broaden its application to other radionuclides (Tarancón et al., 2017).

Although almost all the strategies found in the literature aiming to determine $^{99\text{m}}\text{Tc}$ in urine samples need sample pretreatment, Khan and Um (2015) have developed an interesting, fast, economical method to measure urine samples without radionuclide isolation and sample purification. They use a) a ULG-LLT liquid scintillation cocktail for urine and samples with a high degree of quench, and b) ULG for cleaner samples. This strategy also reduces the precourt delay time published in automated methods (Villar et al., 2015, 2013), from 12h to 2h.

All the strategies mentioned used LSC to determine $^{99\text{m}}\text{Tc}$ in the processed samples.

^{131}I has also been determined from different biological samples from treated patients. In this case the most frequently analysed samples are sweat on skin (Guillot et al., 2016; Hamizah et al., 2012), saliva (Guillot et al., 2016) and urine (Demir et al., 2013). The reported sample collection strategies depend on the type of sample, i.e. direct collection in the case of urine, a wipe test for sweat on the skin surface and Salivette[®] for saliva. The sampling is usually performed some time after the ^{131}I dose is administered, in the range between 4h and 120h. In none of these studies was pretreatment performed, and the samples were measured directly by the use of the different detection systems usually present in NM departments, such as a well counter (Demir et al., 2013), HPGe and activimeter (Guillot et al., 2016) and thyroid uptake probe (Hamizah et al., 2012). The highest activities for ^{131}I , in the order of magnitude of MBq, have been found in urine and saliva samples.

Another sample of concern is the patient's exhaled air, since caregivers or family members could be exposed to internal contamination via the inhalation pathway. In this case samples have been directly collected from the patient (Gründel et al., 2008; Schomäcker et al., 2011) with the aim of determining the total ^{131}I activity and also to investigate the activity related to different exhaled iodine compounds. The reviewed studies that focus on this issue have therefore flowed the air sample through modular support systems. Gründel et al. (2008) collected the exhaled air directly from patients on different adsorbents placed in a modular system that can be adapted depending on the aim

of the iodine species separation, as shown in Fig. 4, a. The maximum exhaled concentration was $2.66 \cdot 10^{-5}$ Bq/m³. Similarly, Fig. 4, b illustrates another collection strategy reported in the literature (Schomäcker et al., 2011). In this case patients filled fifteen balloons, the air from which was then conducted by an air pump into a modular filter system. From both studies it was concluded that the proportion of organic iodine species exhaled by a patient was greater than 90% of the total iodine present in the air sample.

4. Conclusions

Despite the current good practices applied by hospitals with NM departments, several research studies in recent years have demonstrated the presence of medical radionuclides, mainly ^{99m}Tc, ^{99m}Tc and ¹³¹I, in environmental and biological samples. This review compiles and summarizes the most recent developments in determining these radionuclides, in almost all cases using gamma-ray spectrometry and liquid scintillation counting.

As regards the samples tested, in order to successfully analyse these radionuclides in a variety of matrices, different collection and pretreatment strategies have been developed.

In the case of indoor air samples, sampling approaches based on AS have usually been performed, but future trends should focus on the application of real-time strategies comprising both collection and detection steps. This would allow for the determination of short half-life radionuclides, the detection of activity fluctuations and possible evaluation of the occupational dose received in real time.

The existing literature based on biological samples, with urine being the most commonly used matrix, includes automated pretreatment strategies to determine ^{99m}Tc so as to minimize waste generation and avoid sample handling. However, further work is needed to develop automated tools suitable for analysing different types of matrices, such as hospital wastewaters.

Finally, bearing all of this in mind, the future challenge is to develop collection, pretreatment and detection strategies to enable the determination of medical radionuclides that are sensitive enough to assess potential internal occupational contamination and to monitor environmental impacts due to medical radioactive releases.

Uncited reference

ISO, 2006.

References

AENOR, 2016. Water Quality. Determination of the Activity Concentration of Radionuclides. Method by High Resolution Gamma-Ray Spectrometry, (ISO 10703:2007). Madrid.

Andrés, C., Barquero, R., Tortosa, R., Nuñez, C., Del Castillo, A., Vega-Carrillo, H.R., Alonso, D., 2011. ¹³¹I activity in urine to the sewer system due to thyroidal treatments. *Health Phys.* 101, 110–115 <https://doi.org/10.1097/HP.0b013e318209459c>.

ARPANSA, 2008. Safety Guide for Radiation Protection in Nuclear Medicine. Radiation Protection Series Publication, N° 14. 2. [WWW Document]. URL https://www.arpansa.gov.au/sites/default/files/legacy/pubs/rps/rps14_2.pdf, 2.18.19.

Baeza, A., Miró, C., Soletó, C., 2004. Spectrometric determination of low activities of gamma emitters in water samples. *Appl. Radiat. Isot.* 61, 203–206 <https://doi.org/10.1016/j.apradiso.2004.03.046>.

Banerjee, S., Mitra, S., 2013. Radioactive and hospital waste Management: a review. *Int. J. Latest Trends Eng. Technol.* 3, 275–282.

Barquero, R., Agulla, M.M., Ruiz, A., 2008a. Liquid discharges from the use of radionuclides in medicine (diagnosis). *J. Environ. Radioact.* 99, 1535–1538 <https://doi.org/10.1016/j.jenvrad.2007.12.009>.

Barquero, R., Basurto, F., Nuñez, C., Esteban, R., 2008b. Liquid discharges from patients undergoing ¹³¹I treatments. *J. Environ. Radioact.* 99, 1530–1534 <https://doi.org/10.1016/j.jenvrad.2007.12.010>.

Barrera, J., Tarancón, A., Bagán, H., García, J.F., 2016. A new plastic scintillation resin for single-step separation, concentration and measurement of technetium-99. *Anal. Chim. Acta* 936, 259–266 <https://doi.org/10.1016/j.aca.2016.07.008>.

Biersack, H.J., Freeman, L.M., 2007. *Clinical Nuclear Medicine*, first ed. Springer-Verlag Berlin Heidelberg.

Bingham, D., Etherington, G., 2018. Recommendations and standards for monitoring individuals for occupational intakes of radionuclides. *Radiat. Meas.* 115, 69–76 <https://doi.org/10.1016/j.radmeas.2018.06.014>.

Bitar, A., Maghrabi, M., Doubal, A.W., 2016. Evaluation of in vivo and in vitro dose detection limits for different radionuclides and measurement techniques. *Appl. Radiat. Isot.* 113, 5–9 <https://doi.org/10.1016/j.apradiso.2016.04.009>.

Bitar, A., Maghrabi, M., Doubal, A.W., 2013. Assessment of intake and internal dose from iodine-131 for exposed workers handling radiopharmaceutical products. *Appl. Radiat. Isot.* 82, 370–375 <https://doi.org/10.1016/j.apradiso.2013.09.011>.

Bombardier, P., Gensdarmes, F., Daugeron, D., Roche, A., Veyre, A., Giammarile, F., Houzard, C., Fraysse, M., Quisefit, J.-P., 2012. Qualification des émissions d'aérosols radioactifs liées à l'utilisation d'un générateur de technétium en service de médecine nucléaire. *Radioprotection* 47, 521–532 <https://doi.org/10.1051/radiopro/2012019>.

Breustedt, B., Giussani, A., Noßke, D., 2018. Internal dose assessments – concepts, models and uncertainties. *Radiat. Meas.* 115, 49–54 <https://doi.org/10.1016/j.radmeas.2018.06.013>.

Brudecki, K., Szczodry, A., Mróz, T., Kowalska, A., Mietelski, J.W., 2018. Measurement of ¹³¹I activity in air indoor Polish nuclear medical hospital as a tool for an internal dose assessment. *Radiat. Environ. Biophys.* 57, 77–82 <https://doi.org/10.1007/s00411-017-0724-3>.

Camacho, A., Montaña, M., Vallés, I., Devesa, R., Céspedes-Sánchez, R., Serrano, I., 2012. Temporal evolution of radionuclides in sludge from wastewater treatment plants. *J. Radioanal. Nucl. Chem.* 297–306 <https://doi.org/10.1007/s10967-012-1977-6>.

Carneiro, L.G., de Lucena, E.A., Sampaio, C. da S., Dantas, A.L.A., Sousa, W.O., Santos, M.S., Dantas, B.M., 2015. Internal dosimetry of nuclear medicine workers through the analysis of ¹³¹I in aerosols. *Appl. Radiat. Isot.* 100, 70–74 <https://doi.org/10.1016/j.apradiso.2014.11.021>.

Castellani, C., Marsh, J.W., Hurtgen, C., Blanchard, E., Berard, P., Giussani, A., Lopez, M.A., 2013. IDEAS Guidelines (Version 2) for the Estimation of Committed Doses from Incorporation Monitoring Data, EURADOS Report 2013-01 [WWW Document]. URL http://www.eurados-online.de/~media/Files/Eurados/documents/EURADOS_Report_2013-01_online_version.pdf, 2.14.19.

Chain, Y., Illanes, L., 2015. Radiofármacos en medicina nuclear, [WWW Document]. URL http://sedici.unlp.edu.ar/bitstream/handle/10915/46740/Documento_completo.pdf?sequence=1&isAllowed=y, 2.13.19.

Chang, B.U., Choi, S.W., Song, M.H., Lee, J.S., Kim, Y., 2011. Medically used radionuclides (¹³¹I, ^{99m}Tc) in the urban sewage system: the case of the Daejeon metropolitan city, Korea. *Radiat. Protect. Dosim.* 146, 318–321 <https://doi.org/10.1093/rpd/ncr108>.

Clases, D., Sperling, M., Karst, U., 2018. Analysis of metal-based contrast agents in medicine and the environment. *TRAC Trends Anal. Chem. (Reference Ed.)* 104, 135–147 <https://doi.org/10.1016/j.trac.2017.12.011>.

Cosenza, A., Rizzo, S., Sansone Santamaria, A., Viviani, G., 2015. Radionuclides in wastewater treatment plants: monitoring of Sicilian plants. *Water Sci. Technol.* 71, 252–258 <https://doi.org/10.2166/wst.2014.501>.

Damien, P., Guilloux, V., Blanc-Béguin, F., Guillo, P., Salaün, P.Y., 2015. Recherche de contamination atmosphérique dans un service de médecine nucléaire. *Med. Nucl.* 39, 192–198 <https://doi.org/10.1016/j.mednuc.2014.10.001>.

De Massimi, B., Bianchini, D., Sarnelli, A., D'Errico, V., Marcocci, F., Mezzenga, E., Mostacci, D., 2017. Air contamination measurements for the evaluation of internal dose to workers in nuclear medicine departments. *Radiat. Phys. Chem.* 140, 198–201 <https://doi.org/10.1016/j.radphyschem.2017.03.003>.

Demir, M., Parlak, Y., Çavdar, I., Yeyin, N., Tanyildizi, H., Gümtüser, G., Sayit, E., Erees, S., Sayman, H., 2013. The evaluation of urine activity and external dose rate from patients receiving radioiodine therapy for thyroid cancer. *Radiat. Protect. Dosim.* 156, 25–29 <https://doi.org/10.1093/rpd/nct036>.

Díaz-Londoño, G., García, M., Astudillo, R., Hermosilla, A., 2017. Development and implementation of tools for self-monitoring of staff exposed to ¹³¹I in nuclear medicine centres of Chile. *Radiat. Protect. Dosim.* 173, 302–307 <https://doi.org/10.1093/rpd/ncv554>.

Eichrom Technologies, 2014. Technetium-99 in Urine. Method N° TCU01, [WWW Document]. URL https://www.eichrom.com/wp-content/uploads/2018/02/tcu01-13_tc-urine-disc.pdf, 3.3.19.

EN 14175-4, 2004. Fume Cupboards - Part 3: Type Test Methods.

European Commission, 2018. Radiation Protection N° 188. Technical Recommendations for Monitoring Individuals for Occupational Intakes of Radionuclides [WWW Document]. https://ec.europa.eu/energy/sites/ener/files/rp_188.pdf, 1.26.19.

European Commission, 2000. Management of radioactive waste arising from medical establishments in the European Union. In: Proceedings of a Workshop, Brussels, 16-17 February 1999, EUR 19254. Luxembourg.

Ferdous, J., 2016. Assessment of activity concentration and effective doses from bioassay sample of occupational workers in NINMAS, Bangladesh. *Int. J. Radiol. Radiat. Ther.* 1, 8–11 <https://doi.org/10.15406/ijrrt.2016.01.00008>.

Ferdous, J., Sharmin, N., Begum, A., Begum, A., 2017. Airborne radioactivity in hot lab of nuclear medicine. *J. Sci. Res.* 9, 159–166 <https://doi.org/https://doi.org/10.3329/jsr.v9i2.29873>.

Ferdous, M.J., Alam, Z., Khan, R.K., Iqbal, S.M., Islam, A., Rahman, M.A., Begum, A., 2012. Internal radiation monitoring of occupational staff in nuclear medicine facility. *Bangladesh J. Med. Phys.* 5, 63–70 <https://doi.org/https://doi.org/10.3329/bjmp.v5i1.14670>.

Ferrand, O., Brouquières, G., Puech, B., Bussy, E., 2010. Zonage radiologique d'un service de médecine nucléaire: exemple de l'hôpital d'instruction des armées Sainte-Anne. *Med. Nucl.* 34, 664–674 <https://doi.org/10.1016/j.mednuc.2010.10.006>.

- Fischer, H.W., Ulbrich, S., Pittauerová, D., Hettwig, B., 2009. Medical radioisotopes in the environment - following the pathway from patient to river sediment. *J. Environ. Radioact.* 100, 1079–1085 <https://doi.org/10.1016/j.jenvrad.2009.05.002>.
- French Occupational Health Medicine Society, 2011. Good Practice Recommendations. Medical Monitoring of Occupational Internal Exposure to Radionuclides in Nuclear Installations [WWW Document]. http://www.chu-rouen.fr/sfmt/autres/Internal_exposure_nuclear_instal_medical_monitoring_nov_2012.pdf, 2.25.19.
- Giardina, M., Tomarchio, E., Greco, D., 2015. Analysis of radionuclide concentration in air released through the stack of a radiopharmaceutical production facility based on a medical cyclotron. *Radiat. Phys. Chem.* 116, 368–372 <https://doi.org/10.1016/j.radphyschem.2015.04.020>.
- Gilfillan, N.R., Timmers, H., 2012. Detection and tracing of the medical radioisotope ^{131}I in the Canberra environment. *EPJ Web Conf.* 35, 1–4 <https://doi.org/10.1051/epjconf/20123504002>.
- González-García, C.M., González, J.F., Román, S., 2011. Removal efficiency of radioactive methyl iodide on TEDA-impregnated activated carbons. *Fuel Process. Technol.* 92, 247–252 <https://doi.org/10.1016/j.fuproc.2010.04.014>.
- Gourani, M., Sadighzadeh, A., Mizani, F., 2014. Effect of impregnating materials in activated carbon on Iodine-131 (^{131}I) removal efficiency. *Radiat. Protect. Environ.* 37, 179–183 <https://doi.org/10.4103/0972-0464.154882>.
- Gründel, M., Kopka, B., Schulz, R., 2008. ^{131}I exhalation by patients undergoing therapy of thyroid diseases. *Radiat. Protect. Dosim.* 129, 435–438 <https://doi.org/10.1093/rpd/nem459>.
- Guillot, S., Tylski, P., Scheiber, C., Bournaud-Salinas, C., Bolot, C., Harthe, C., Jalade, P., 2016. Quantification des risques de contamination et d'exposition externe du personnel en radiothérapie interne vectorisée par iode-131. *Radioprotection* 51, 171–177 <https://doi.org/10.1051/radiopro/2016030>.
- Hamizah, N., Juliana, M., Waidi, A., Ismalina, S., Ahmad, Z., 2012. Surface contamination in skin and room during hospitalization of thyroid cancer patient receiving radioiodine ablation. *IOSR J. Dent. Med. Sci.* 2, 27–33.
- Happel, C., Kratzel, U., Selinski, I., Bockisch, B., Etzel, M., Korkusuz, H., Sauter, B., Staudt, J., von Müller, F., Grünwald, F., Kranert, W.T., 2013. Incorporation monitoring of employees of a radioiodine therapy ward. Is incorporation monitoring required for routine? *Nuklearmedizin* 52, 43–50 <https://doi.org/10.3413/Nukmed-0522-12-07>.
- Hoi, T.X., Phuong, H.T., Van Hung, N., 2017. Estimating the internal dose for ^{131}I production workers from air sampling method. *Radiat. Protect. Dosim.* 175, 58–64 <https://doi.org/10.1093/rpd/ncw269>.
- Hoi, T.X., Phuong, H.T., Van Hung, N., 2016. Using smartphone as a motion detector to collect time-microenvironment data for estimating the inhalation dose. *Appl. Radiat. Isot.* 115, 267–273 <https://doi.org/10.1016/j.apradiso.2016.06.024>.
- Hormann, V., Fischer, H.W., 2017. The physicochemical distribution of ^{131}I in a municipal wastewater treatment plant. *J. Environ. Radioact.* 178–179, 55–62 <https://doi.org/10.1016/j.jenvrad.2017.07.008>.
- Hou, X., 2011. Analysis of urine for pure beta emitters: methods and application. *Health Phys.* 101, 159–169 <https://doi.org/10.1097/HP.0b013e31821497c0>.
- Huve, J., Ryzhikov, A., Nouali, H., Lalia, V., Augé, G., Daou, T.J., 2018. Porous sorbents for the capture of radioactive iodine compounds: a review. *RSC Adv.* 8, 29248–29273 <https://doi.org/10.1039/c8ra04775h>.
- International Atomic Energy Agency (IAEA), 2018. Occupational Radiation Protection. General Safety Guide No. GSG-7 [WWW Document]. https://www-pub.iaea.org/MTCD/Publications/PDF/PUB1785_web.pdf, 3.2.19.
- International Atomic Energy Agency (IAEA), 2009. Release of patients after radionuclide therapy/with contributions from the international commission on radiological protection. Safety Reports Series No. 63 [WWW Document]. URL https://www-pub.iaea.org/MTCD/publications/PDF/pub1417_web.pdf, 2.23.19.
- International Atomic Energy Agency (IAEA), 1999. Assessment of Occupational Exposure Due to Intakes of Radionuclides, Safety Guide No. RS-G-1.2 [WWW Document]. URL https://www-pub.iaea.org/MTCD/Publications/PDF/P077_scr.pdf, 2.23.19.
- ISO, 2016. Radiological Protection — Monitoring and Internal Dosimetry for Staff Members Exposed to Medical Radionuclides as Unsealed Sources (ISO 16637:2016), (Switzerland).
- ISO, 2006. Radiation Protection — Monitoring of Workers Occupationally Exposed to a Risk of Internal Contamination with Radioactive Material (ISO 20553:2006).
- Janssens, A., Necheva, C., Tanner, V., Turai, I., 2013. The new Basic Safety Standards Directive and its implications for environmental monitoring. *J. Environ. Radioact.* 125, 99–104 <https://doi.org/10.1016/j.jenvrad.2012.12.008>.
- Jeong, G., Jang, H., Kim, J., Lee, J., 2011. Estimation of concentrations and committed effective doses from urine samples of nuclear medicine workers in Korea due to inhalation of ^{131}I . *Prog. Nucl. Sci. Technol.* 1, 541–544 <https://doi.org/10.15669/pnst.1.541>.
- Jiemwuthisak, P., Sritongkul, N., Chaudakhetrin, P., Kanchanaphiboon, P., Tuntawiroon, M., 2012. Air monitoring to control the intake of airborne radioiodine-131 contaminants by nuclear medicine workers. In: 6th Annual Scientific Meeting on Challenges of Quality Assurance in Radiation Medicine. Phitsanulok, Thailand.
- Jiménez, F., Deban, L., Pardo, R., García-Talavera, P., 2012. Combination of liquid scintillation counting and passive sampling strategy for the determination of I-131 in air and application to estimate the inhalation dose to the staff of a nuclear medicine service. *J. Environ. Sci. Health Part A Toxic Hazard. Subst. Environ. Eng.* 47, 1843–1848 <https://doi.org/10.1080/10934529.2012.689550>.
- Jiménez, F., Deban, L., Pardo, R., López, R., García-Talavera, M., 2011a. Levels of ^{131}I and six natural radionuclides in sludge from the sewage treatment plant of Valladolid, Spain. *Water Air Soil Pollut.* 217, 515–521 <https://doi.org/10.1007/s11270-010-0605-8>.
- Jiménez, F., López, R., Pardo, R., Deban, L., García-Talavera, M., 2011b. The determination and monitoring of ^{131}I activity in sewage treatment plants based on A2/O processes. *Radiat. Meas.* 46, 104–108 <https://doi.org/10.1016/j.radmeas.2010.07.030>.
- Kaplan, D.I., Denham, M.E., Zhang, S., Yeager, C., Xu, C., Schwehr, K.A., Li, H.P., Ho, Y.F., Wellman, D., Santschi, P.H., 2014. Radioiodine biogeochemistry and prevalence in groundwater. *Crit. Rev. Environ. Sci. Technol.* 44, 2287–2335 <https://doi.org/10.1080/10643389.2013.828273>.
- Kawase, S., Ohno, K., Miyatake, H., 2015. Safety management of nuclear medicine personnel with visualisation of air dose rate. *Radiat. Protect. Dosim.* 165, 439–442 <https://doi.org/10.1093/rpd/ncv120>.
- Khan, M., Um, W., 2015. Liquid scintillation counting methodology for ^{99}Tc analysis: a remedy for radiopharmaceutical waste. *Anal. Chem.* 87, 9054–9060 <https://doi.org/10.1021/acs.analchem.5b02279>.
- Kim, J.H., Whang, J., 2009. Measuring the daily rate of radioactive iodine (^{131}I) uptake in the thyroid glands and excretion through the urine of Korean adult males. *J. Nucl. Sci. Technol.* 46, 12–17 <https://doi.org/10.1080/18811248.2007.9711501>.
- Kim, S., Yoo, J., Park, M.J., 2018. An investigation into internal exposure management needs for nuclear medicine practitioners and temporary visitors through I-131 internal dose assessment: focusing on large hospitals in South Korea. *PLoS One* 13, 1–15 <https://doi.org/https://doi.org/10.1371/journal.pone.0209244>.
- Kopisch, A., Martin, C.B., Grantham, V., 2011. Exposure to technologists from preparing and administering therapeutic ^{131}I : how frequently should we bioassay?. *J. Nucl. Med. Technol.* 39, 60–62 <https://doi.org/10.2967/jnmt.110.077297>.
- Krawczyk, E., Piñero-García, F., Ferro-García, M.A., 2013. Discharges of nuclear medicine radioisotopes in Spanish hospitals. *J. Environ. Radioact.* 116, 93–98 <https://doi.org/10.1016/j.jenvrad.2012.08.011>.
- Leners, N., Sinnen, C., Kaphammel, O., Schreiner, A., Als, C., 2011. Procédures de ventilation pulmonaire par aérosol ^{99m}Tc -DTPA: contamination aérienne, contaminations interne et cutanée externe des manipulateurs. *Med. Nucl.* 35, 553–557 <https://doi.org/10.1016/j.mednuc.2011.07.005>.
- Lucena, E.A., Rebelo, A.M.O., Araújo, F., Sousa, W.O., Dantas, A.L.A., Dantas, B.M., Corbo, R., 2007. Evaluation of internal exposure of nuclear medicine staff through in vivo and in vitro bioassay techniques. *Radiat. Protect. Dosim.* 127, 465–468 <https://doi.org/10.1093/rpd/ncm365>.
- Malta, M., Oliveira, J.M., Silva, L., Carvalho, F.P., 2013. Radioactivity from Lisboa urban wastewater discharges in the Tejo river estuary. *Rev. Gestão Costeira Integr.* 13, 399–408 <https://doi.org/10.5894/rgci339>.
- Martínez, J., Baciu, T., Artigues, M., Danús, M., Peñalver, A., Aguilar, C., Borrull, F., n.d. Nuclear medicine: workplace monitoring and internal occupational exposure during a ventilation/perfusion single photon emission tomography. *Radiat. Environ. Biophys.*
- Martínez, J., Baciu, T., Peñalver, A., Aguilar, C., Borrull, F., 2019. The partitioning of ^{131}I in sludge samples from a wastewater treatment plant. *J. Radioanal. Nucl. Chem.* 319, 1243–1250 <https://doi.org/https://doi.org/10.1007/s10967-019-06431-x>.
- Martínez, J., Peñalver, A., Baciu, T., Artigues, M., Danús, M., Aguilar, C., Borrull, F., 2018. Presence of artificial radionuclides in samples from potable water and wastewater treatment plants. *J. Environ. Radioact.* 192, 187–193 <https://doi.org/10.1016/j.jenvrad.2018.06.024>.
- Matheoud, R., Cannillo, B., Sacchetti, G.M., Brambilla, M., 2018. [OA199] Internal contamination monitoring of workers in a nuclear medicine department: results of one year routine monitoring. *Abstr. Med.* 52, 1–98 <https://doi.org/10.1016/j.ejmp.2018.06.271>.
- Mietelski, J.W., Grabowska, S., Nowak, T., Bogacz, J., Gaca, P., Bartyzel, M., Budzanowski, M., 2005. Inhalation dose due to presence of ^{131}I in air above septic tank system of an endocrinology hospital. *Radiat. Prot. Dosimetry* 117, 395–401 <https://doi.org/10.1093/rpd/nci306>, 2005.
- Montenero, M.P., Dilbone, E.K., Waples, J.T., 2017a. Using medically-derived iodine-131 to track sewage effluent in the Laurentian Great Lakes. *Water Res.* 123, 773–782 <https://doi.org/10.1016/j.watres.2017.07.022>.
- Montenero, M.P., Dilbone, E.K., Waples, J.T., 2017b. The removal of particle-reactive radionuclides in shallow water: bottom scavenging versus particle settling of iodine-131 and beryllium-7. *J. Environ. Radioact.* 177, 128–134 <https://doi.org/10.1016/j.jenvrad.2017.06.013>.
- Morita, T., Niwa, K., Fujimoto, K., Kasai, H., Yamada, H., Nishiutchi, K., Sakamoto, T., Godo, W., Taino, S., Hayashi, Y., Takeno, K., Nishigaki, T., Fujiwara, K., Aratake, H., Kamonoshita, S., Hashimoto, H., Kobayashi, T., Otosaka, S., Imanaka, T., 2010. Detection and activity of iodine-131 in brown algae collected in the Japanese coastal areas. *Sci. Total Environ.* 408, 3443–3447 <https://doi.org/10.1016/j.scitotenv.2010.04.001>.
- Mról, T., Brudecki, K., Mietelski, J.W., Bartyzel, M., Misiak, R., 2018. Medical activated charcoal tablets as a cheap tool for passive monitoring of gaseous ^{131}I activity in air of nuclear medicine departments. *J. Radioanal. Nucl. Chem.* 723–726 <https://doi.org/10.1007/s10967-018-6107-7>.
- Mulas, D., Camacho, A., Garbayo, A., Devesa, R., Duch, M.A., 2019. Medically-derived radionuclides levels in seven heterogeneous urban wastewater treatment plants: the role of operating conditions and catchment area. *Sci. Total Environ.* 663, 818–829 <https://doi.org/10.1016/j.scitotenv.2019.01.349>.
- Nandanwar, S.U., Coldsnow, K., Utgikar, V., Sabharwal, P., Eric Aston, D., 2016. Capture of harmful radioactive contaminants from off-gas stream using porous solid sorbents for clean environment – a review. *Chem. Eng. J.* 306, 369–381 <https://doi.org/10.1016/j.cej.2016.07.073>.

- Noh, S., Jeong, S., An, M., Jang, H.K., Kwon, T.E., Lee, J.I., Park, T.J., Lee, J.K., 2016. Internal dosimetry for intake of ^{18}F FDG using spot urine sample. *Radiat. Protect. Dosim.* 168, 343–349 <https://doi.org/10.1093/rpd/ncv346>.
- Orsini, F., Lorenzoni, A., Erba, P.A., Mariani, G., 2010. Radiopharmaceuticals for single-photon emission imaging and for therapy. In: Strauss, H.W. (Ed.), *Nuclear Oncology: Pathophysiology and Clinical Applications*. Springer Science + Business Media, New York <https://doi.org/10.1007/978-0-387-48894-3>.
- Palomo, M., Peñalver, A., Aguilar, C., Borrull, F., 2010. Presence of Naturally Occurring Radioactive Materials in sludge samples from several Spanish water treatment plants. *J. Hazard Mater.* 181, 716–721 <https://doi.org/10.1016/j.jhazmat.2010.05.071>.
- Paquet, F., Etherington, G., Bailey, M.R., Leggett, R.W., Lipsztein, J., Bolch, W., Eckermann, J.D.H., 2015. Occupational intakes of radionuclides: Part 1. ICRP publication 130. *Ann. ICRP* 44, 5–188 <https://doi.org/https://doi.org/10.1177/0146645315577539>.
- Peekhuthod, D., Bangvirunrak, J., Sansakon, S., Nukultham, A., Pukkhaw, T., 2017. Baseline quantity of ^{131}I , ^{137}Cs , ^{134}Cs and ^{40}K in urinary excretions from Thai people and internal exposure dose. *J. Phys. Conf. Ser.* 860, 1–7 <https://doi.org/10.1088/1742-6596/860/1/012038>.
- Petrucchi, C., Traino, A.C., 2015. Focus on the legislative approach to short half life radioactive hospital waste releasing. *Phys. Med.* 31, 726–732 <https://doi.org/10.1016/j.ejmp.2015.06.001>.
- Punt, A., Wood, M., Rose, D., 2007. Radionuclide discharges to sewer – a field investigation Science Report - SC020150/SR2 [WWW Document]. In: <http://www.phillywatersheds.org/doc/ThamesEstuaryIodineSourceStudy.pdf>, 2.8.19.
- Qaim, S.M., 2017. Nuclear data for production and medical application of radionuclides: present status and future needs. *Nucl. Med. Biol.* 44, 31–49 <https://doi.org/10.1016/j.nucmedbio.2016.08.016>.
- Ravichandran, R., 2017. Management of radioactive wastes in a hospital environment. In: Sengupta, D., Agrahari, S. (Eds.), *Modelling Trends in Solid and Hazardous Waste Management*. Springer Science + Business Media, Singapore <https://doi.org/10.1007/978-981-10-2410-8>.
- Rodríguez-Laguna, A., Estrada-Lobato, E., Brandan, M., Medina, L., 2010. ^{131}I intake survey and effective dose calculation for personnel in a nuclear medicine department. *Rev. Fis Med.* 11, 43–54.
- Rodríguez, J., 2012. BioChroma - a new and patented technology for processing radioactive wastewater from nuclear medicine therapy facilities in hospitals and clinics. *World J. Nucl. Med.* 11, 12–18 <https://doi.org/10.4103/1450-1147.98735>.
- Rodríguez, R., Avivar, J., Leal, L.O., Cerdà, V., Ferrer, L., 2016. Strategies for automating solid-phase extraction and liquid-liquid extraction in radiochemical analysis. *TrAC Trends Anal. Chem. (Reference Ed.)* 76, 145–152 <https://doi.org/10.1016/j.trac.2015.09.009>.
- Rose, P.S., Smith, J.P., Aller, R.C., Swanson, R.L., 2013. Behavior of medically-derived ^{131}I in the tidal potomac river. *Sci. Total Environ.* 452–453, 87–97 <https://doi.org/10.1016/j.scitotenv.2013.01.055>.
- Rose, P.S., Swanson, R.L., 2013. Iodine-131 in sewage sludge from a small water pollution control plant serving a thyroid cancer treatment facility. *Health Phys.* 105, 115–120 <https://doi.org/10.1097/HP.0b013e31828459ef>.
- Rose, P.S., Swanson, R.L., Cochran, J.K., 2012. Medically-derived ^{131}I in municipal sewage effluent. *Water Res.* 46, 5663–5671 <https://doi.org/10.1016/j.watres.2012.07.045>.
- Saha, G., 2004. *Fundamentals of Nuclear Pharmacy*, fifth ed. Springer Verlag, New York.
- Schomäcker, K., Fischer, T., Zimmermanns, B., Bregulla, J., Sudbrock, F., Prante, O., Drzezga, A., 2017. Retention efficacy and release of radioiodine in fume hoods. *J. Environ. Radioact.* 166, 175–180 <https://doi.org/10.1016/j.jenvrad.2016.01.006>.
- Schomäcker, K., Sudbrock, F., Fischer, T., Dietlein, M., Kobe, C., Gaidouk, M., Schicha, H., 2011. Exhalation of ^{131}I after radioiodine therapy: measurements in exhaled air. *Eur. J. Nucl. Med. Mol. Imaging* 38, 2165–2172 <https://doi.org/10.1007/s00259-011-1888-8>.
- Shoji, M., Kondo, T., Honoki, H., Nakajima, T., Muraguchi, A., Saito, M., 2007. Investigation of monitoring for internal exposure by urine bioassay in a biomedical research facility. *Radiat. Protect. Dosim.* 127, 456–460 <https://doi.org/10.1093/rpd/ncm409>.
- Smith, J.P., Oktay, S.D., Kada, J., Olsen, C.R., 2008. Iodine-131: a potential short-lived, wastewater-specific particle tracer in an urbanized estuarine system. *Environ. Sci. Technol.* 42, 5435–5440 <https://doi.org/10.1021/es800418c>.
- Sudbrock, F., Schomäcker, K., Drzezga, A., 2017. The effectiveness of wastewater treatment in nuclear medicine: performance data and radioecological considerations. *J. Environ. Radioact.* 166, 202–207 <https://doi.org/10.1016/j.jenvrad.2016.04.002>.
- Suhariyono, G., Bunawas, 2015. Comparative analysis of direct and indirect ^{131}I measurement methods from the stack to outdoor. *At. Indones.* 43, 127–136 <https://doi.org/https://doi.org/10.17146/aj.2017.756>.
- Sundell-Bergman, S., de la Cruz, I., Avila, R., Hasselblad, S., 2008. A new approach to assessment and management of the impact from medical liquid radioactive waste. *J. Environ. Radioact.* 99, 1572–1577 <https://doi.org/10.1016/j.jenvrad.2007.12.005>.
- Sundell-Bergman, S., Sigurgeirsson, M., Avila, R., Cruz, I. de la, Xu, S., Puhakainen, M., Heikkinene, T., Rahola, T., Hosseini, A., Nielsen, S., Nordisk, Kernesikkerhedsforskning, 2009. NKS-B LUCIA: assessing the impact of releases of radionuclides into sewage systems in urban environment - simulation, modelling and experimental studies. In: *Kernesikkerhedsforskning, Nordisk (Ed.)*, Proceedings of the NKS-R and NKS-B Joint Summary Seminar. Roskilde.
- Taracón, A., Bagán, H., García, J.F., 2017. Plastic scintillators and related analytical procedures for radionuclide analysis. *J. Radioanal. Nucl. Chem.* 314, 555–572 <https://doi.org/10.1007/s10967-017-5494-5>.
- Uhrhan, K., Drzezga, A., Sudbrock, F., 2014. The patient as a radioactive source: an inter-comparison of survey meters for measurements in nuclear medicine. *Radiat. Protect. Dosim.* 162, 101–104 <https://doi.org/10.1093/rpd/ncu238>.
- Veliscek Carolan, J., Hughes, C.E., Hoffmann, E.L., 2011. Dose assessment for marine biota and humans from discharge of ^{131}I to the marine environment and uptake by algae in Sydney, Australia. *J. Environ. Radioact.* 102, 953–963 <https://doi.org/10.1016/j.jenvrad.2009.10.002>.
- Villar, M., Avivar, J., Ferrer, L., Borràs, A., Vega, F., Cerdà, V., 2015. Automatic in-syringe dispersive liquid-liquid microextraction of ^{99}Tc from biological samples and hospital residues prior to liquid scintillation counting. *Anal. Bioanal. Chem.* 407, 5571–5578 <https://doi.org/10.1007/s00216-015-8761-8>.
- Villar, M., Avivar, J., Ferrer, L., Galmés, M., Vega, F., Cerdà, V., 2013. Automatic and simple method for ^{99}Tc determination using a selective resin and liquid scintillation detection applied to urine samples. *Anal. Chem.* 85, 5491–5498 <https://doi.org/10.1021/ac4006217>.
- Yamamoto, S., Kato, K., Fujita, N., Yamashita, M., Nishimoto, T., Kameyama, H., Abe, S., 2018. Detection of alpha radionuclides in air from patients during Ra-223 alpha radionuclide therapy. *Sci. Rep.* 8, 1–6 <https://doi.org/10.1038/s41598-018-29449-9>.
- Zannoni, D., Cantaluppi, C., Ceccotto, F., Giacetti, W., Lovisetto, B., 2019. Human and environmental factors affecting the activity of ^{131}I and ^{137}Cs in urban wastewater: a case study. *J. Environ. Radioact.* 198, 135–146 <https://doi.org/10.1016/j.jenvrad.2018.12.026>.
- Zimmermann, R., 2006. *Nuclear Medicine. Radioactivity for Diagnosis and Therapy*. EDP Sciences.